Jardiance Met 12.5mg/500mg (Empagliflozin/Metformin)

Description

Introduction

Jardiance Met 12.5mg/500mg is an oral tablet containing empagliflozin and metformin. It is presented for the management of type 2 diabetes. The ingredients lower blood glucose through different mechanisms. The choice of treatment depends on a person’s medical history, kidney function and other medicines.

What Is It?

Each tablet contains 12.5 mg of empagliflozin and 500 mg of metformin. This is a fixed-dose combination: both ingredients are supplied together at set strengths. The product page identifies it as a tablet but does not specify whether it has an immediate-release or extended-release formulation. Ask a healthcare professional for product-specific guidance if the release type matters to a treatment plan.

How Does It Work?

Empagliflozin is a sodium-glucose co-transporter 2, or SGLT2, inhibitor. It reduces the amount of glucose reabsorbed by the kidneys, allowing more glucose to leave the body in urine. Metformin is a biguanide. It mainly reduces glucose production by the liver and helps the body respond to insulin. These different actions can improve blood glucose control alongside diet and physical activity.

Common Uses

The empagliflozin and metformin combination is used to improve blood glucose control in type 2 diabetes when a clinician considers both ingredients appropriate. It may be used alongside certain other diabetes medicines. This combination is not intended to treat type 1 diabetes or diabetic ketoacidosis. Its suitability for a particular person requires clinical assessment.

Available Strengths

This family is available in 5 mg, 12.5 mg.

Key Features

• Contains empagliflozin and metformin in one oral tablet.
• Provides 12.5 mg empagliflozin and 500 mg metformin per tablet.
• Combines an SGLT2 inhibitor with a biguanide.
• Has a fixed ingredient ratio, so the amounts of the two ingredients cannot be adjusted independently within the tablet.

Benefits

• The ingredients act through different pathways to lower blood glucose.
• Using both ingredients can improve blood glucose measures when combination treatment is clinically appropriate.
• One fixed-dose tablet supplies both ingredients, which may reduce the number of separate tablets in a prescribed regimen.

Individual results vary. Benefits shown for an ingredient or a different brand should not be assumed to apply to every use of this product.

Possible Side Effects

• Metformin can cause nausea, diarrhoea, stomach discomfort, vomiting or reduced appetite. These effects may be more noticeable when treatment begins.
• Empagliflozin can cause increased urination and thirst. Genital fungal infections may also occur.
• Urinary tract infections and dehydration are possible. Painful urination, fever, dizziness or unusual thirst should be discussed with a healthcare professional.
• Low blood glucose is more likely when the combination is used with insulin or a sulfonylurea.
• Rare but serious problems include diabetic ketoacidosis and metformin-associated lactic acidosis. Persistent vomiting, abdominal pain, difficulty breathing, marked weakness or confusion need urgent medical assessment.

Precautions

• Kidney function affects whether this combination is appropriate. A clinician may assess kidney function before treatment and monitor it during treatment.
• A history of ketoacidosis, liver disease, recurrent genital or urinary infections, or dehydration should be discussed before use.
• Pregnancy, planned pregnancy and breastfeeding require a review of treatment options with a healthcare professional.
• Anyone with a known allergy to empagliflozin, metformin or another tablet ingredient should obtain professional advice before use.

Additional Precautions

• Serious illness, prolonged fasting, major surgery or substantial fluid loss can change the risks associated with these ingredients. A clinician can advise whether treatment needs temporary adjustment.
• Metformin-associated lactic acidosis is rare but serious. Kidney impairment, dehydration and excessive alcohol intake are among the factors that can increase its risk.
• Ketoacidosis associated with SGLT2 inhibitors can occur even when blood glucose is not markedly raised. Nausea, abdominal pain, difficulty breathing or unusual tiredness warrant urgent assessment.
• New pain, redness or swelling around the genitals or perineum needs immediate medical attention because a rare, serious infection is possible.
• Foot sores or signs of infection should be assessed promptly as part of routine diabetes care.

Storage Instructions

• Keep tablets in their supplied packaging until use and protect them from excess heat and moisture.
• Keep all medicines out of sight and reach of children.
• Check the supplied pack for its specific storage temperature and expiry date. Ask a pharmacist if either detail is unclear.
• Ask a pharmacist how to dispose of tablets that are expired or no longer needed.

How to Take

• Follow the directions provided by the prescribing healthcare professional and the instructions supplied with the particular pack. The dose and schedule are individual decisions.
• Metformin can cause stomach-related effects, and food may help reduce them. Ask a pharmacist how this specific tablet should be taken with meals.
• Ask a pharmacist what to do about a missed tablet rather than changing the schedule independently.
• Do not substitute a different strength or change treatment without professional advice.

Drug Interactions

• Insulin and sulfonylureas can increase the likelihood of low blood glucose when used with this combination.
• Diuretics may increase fluid loss. Medicines that affect kidney function can also alter treatment risks and may require monitoring.
• Iodinated contrast used for some scans may require a temporary change to metformin treatment, depending on kidney function and the procedure.
• Excessive alcohol intake increases concern about metformin-associated lactic acidosis.
• Give a clinician or pharmacist a complete list of prescription medicines, over-the-counter products and supplements for an interaction check.

Why Choose This Product?

• It provides the stated empagliflozin and metformin strengths together in one tablet.
• The ingredients lower blood glucose through different mechanisms.
• Its fixed-dose format may fit a treatment plan that calls for these exact ingredient strengths.

Selection depends on clinical needs and the details of the supplied pack. Ask a healthcare professional for product-specific guidance.

Frequently Asked Questions (FAQs)

What ingredients does each tablet contain?

Each tablet contains 12.5 mg empagliflozin and 500 mg metformin.

What condition is this combination used for?

It is used to help manage blood glucose in type 2 diabetes when both ingredients are appropriate.

Is it used for type 1 diabetes?

No. This combination is not intended to treat type 1 diabetes.

Is it an extended-release tablet?

The product details do not establish its release type. Check the supplied pack or ask a pharmacist.

Does it replace diet and physical activity?

No. Medicines for blood glucose control are generally used alongside a broader diabetes management plan.

Can it cause low blood glucose?

The risk rises when it is combined with insulin or certain other diabetes medicines, particularly sulfonylureas.

Why might kidney tests be needed?

Kidney function affects treatment suitability and helps clinicians assess the risk of adverse effects.

What if stomach upset occurs?

Speak with a healthcare professional if symptoms persist or are severe. A pharmacist can explain whether taking the supplied tablet with food is appropriate.

Can it be used during pregnancy?

Pregnancy requires individual medical review. A healthcare professional can discuss treatment options.

Is this the same as empagliflozin alone?

No. This tablet also contains metformin, which has a different glucose-lowering action.

Related Products

• Jardiance Met 5mg/500mg (Empagliflozin/Metformin)
• Jardiance Met 12.5mg/500mg (Empagliflozin/Metformin)
• Glimepiride 4 mg Australia
• Voglibose 0.3 mg Australia
• Repaglinide 1 mg Australia
• Acarbose 25 mg Australia